NEXT Financial Group Inc lowered its stake in shares of Allergan PLC. (NYSE:AGN) by 6.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,068 shares of the company’s stock after selling 75 shares during the period. NEXT Financial Group Inc’s holdings in Allergan PLC. were worth $260,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in AGN. Israel Discount Bank of New York purchased a new position in shares of Allergan PLC. during the first quarter valued at about $988,000. Trust Co. of Vermont increased its position in shares of Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after buying an additional 1,109 shares during the period. Capital Planning Advisors LLC increased its position in shares of Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock valued at $878,000 after buying an additional 1,625 shares during the period. First Long Island Investors LLC purchased a new position in shares of Allergan PLC. during the first quarter valued at about $4,826,000. Finally, Rehmann Capital Advisory Group increased its position in shares of Allergan PLC. by 15.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,780 shares of the company’s stock valued at $425,000 after buying an additional 237 shares during the period. 83.63% of the stock is owned by institutional investors.

Shares of Allergan PLC. (NYSE:AGN) traded down 0.35% during midday trading on Friday, reaching $223.99. 2,006,235 shares of the company’s stock traded hands. The firm has a market capitalization of $74.88 billion, a P/E ratio of 6.82 and a beta of 1.16. The stock’s 50 day moving average price is $243.31 and its 200 day moving average price is $238.68. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the prior year, the firm posted $3.35 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. On average, equities research analysts anticipate that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

TRADEMARK VIOLATION WARNING: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/20/next-financial-group-inc-has-260000-position-in-allergan-plc-agn.html.

AGN has been the subject of several analyst reports. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. Sanford C. Bernstein reissued an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Mizuho reduced their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cantor Fitzgerald initiated coverage on shares of Allergan PLC. in a report on Friday, June 16th. They set a “neutral” rating and a $231.00 price target for the company. Finally, Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price target for the company in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $275.49.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.